JP2023522630A5 - - Google Patents

Info

Publication number
JP2023522630A5
JP2023522630A5 JP2022562446A JP2022562446A JP2023522630A5 JP 2023522630 A5 JP2023522630 A5 JP 2023522630A5 JP 2022562446 A JP2022562446 A JP 2022562446A JP 2022562446 A JP2022562446 A JP 2022562446A JP 2023522630 A5 JP2023522630 A5 JP 2023522630A5
Authority
JP
Japan
Prior art keywords
antigen
amino acid
antibody
flt3
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022562446A
Other languages
English (en)
Japanese (ja)
Other versions
JP7679399B2 (ja
JP2023522630A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/059646 external-priority patent/WO2021209495A1/en
Publication of JP2023522630A publication Critical patent/JP2023522630A/ja
Publication of JP2023522630A5 publication Critical patent/JP2023522630A5/ja
Application granted granted Critical
Publication of JP7679399B2 publication Critical patent/JP7679399B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022562446A 2020-04-14 2021-04-14 抗ｆｌｔ３抗体及び組成物 Active JP7679399B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009578P 2020-04-14 2020-04-14
US63/009,578 2020-04-14
PCT/EP2021/059646 WO2021209495A1 (en) 2020-04-14 2021-04-14 Anti-flt3 antibodies and compositions

Publications (3)

Publication Number Publication Date
JP2023522630A JP2023522630A (ja) 2023-05-31
JP2023522630A5 true JP2023522630A5 (https=) 2024-04-22
JP7679399B2 JP7679399B2 (ja) 2025-05-19

Family

ID=75530015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022562446A Active JP7679399B2 (ja) 2020-04-14 2021-04-14 抗ｆｌｔ３抗体及び組成物

Country Status (16)

Country Link
US (2) US12252539B2 (https=)
EP (1) EP4136114A1 (https=)
JP (1) JP7679399B2 (https=)
KR (1) KR20220167331A (https=)
CN (1) CN115715297A (https=)
AU (1) AU2021255884A1 (https=)
BR (1) BR112022020683A2 (https=)
CA (1) CA3180188A1 (https=)
CL (1) CL2022002833A1 (https=)
CO (1) CO2022014520A2 (https=)
IL (1) IL297269A (https=)
MX (1) MX2022012919A (https=)
PE (1) PE20230075A1 (https=)
PH (1) PH12022552710A1 (https=)
TW (1) TWI910146B (https=)
WO (1) WO2021209495A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115715297A (zh) * 2020-04-14 2023-02-24 法国施维雅药厂 抗flt3抗体和组合物
WO2024108163A2 (en) * 2022-11-18 2024-05-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to cd135 polypeptides
EP4637816A1 (en) * 2022-12-22 2025-10-29 The Medical College of Wisconsin, Inc. Compositions that target cd138 and cd3 and methods of making and using the same
AU2024293963A1 (en) * 2023-07-12 2026-02-26 Phenomic Ai Anti-cthrc1 t cell engagers and methods of using the same
CN118924724B (zh) * 2024-07-29 2025-11-04 湖南大学 一种用于治疗神经母细胞瘤的药物组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7832394A (en) 1993-09-08 1995-03-27 Imclone Systems Incorporated Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
JP2004529102A (ja) 2000-10-24 2004-09-24 イミュネックス・コーポレーション 併用療法を用いて、腫瘍を治療する方法
AR071891A1 (es) 2008-05-30 2010-07-21 Imclone Llc Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
DK2516468T3 (en) 2009-12-23 2016-05-23 Synimmune Gmbh ANTI-FLT3 ANTIBODIES AND METHODS FOR USING THESE
CA2961950A1 (en) 2014-09-28 2016-03-31 The Regents Of The University Of California Modulation of stimulatory and non-stimulatory myeloid cells
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
AU2017382883B2 (en) * 2016-12-21 2024-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
MY201312A (en) 2017-06-02 2024-02-16 Pfizer Antibodies specific for flt3 and their uses
SG10202108528QA (en) 2017-06-02 2021-09-29 Pfizer Chimeric antigen receptors targeting flt3
JP7495409B2 (ja) 2018-09-11 2024-06-04 ドイチェス クレブスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェンレヒツ 改善された抗ｆｌｔ３抗原結合タンパク質
SG11202104352XA (en) * 2018-12-18 2021-05-28 Boehringer Ingelheim Io Canada Inc Flt3 agonist antibodies and uses thereof
CN115715297A (zh) * 2020-04-14 2023-02-24 法国施维雅药厂 抗flt3抗体和组合物

Similar Documents

Publication Publication Date Title
JP2023522630A5 (https=)
CN107312091B (zh) 靶向人cd19抗原的人源化单克隆抗体
CN105189562B (zh) Il-15异源二聚体蛋白及其用途
JP2024527606A5 (https=)
JP2021511811A5 (https=)
Chen et al. A bispecific antibody targeting HER2 and PD-L1 inhibits tumor growth with superior efficacy
JP2018529359A5 (https=)
JP2020109101A (ja) 幹細胞増強治療法
JP7689200B2 (ja) 抗ｃｎｔｎ４特異的抗体及びその使用
JP2024521472A5 (https=)
US11021538B2 (en) Bispecific coupled antibody, preparation method and application thereof
CN117050165B (zh) 一种靶向猴痘病毒的抗体、其抗原结合片段及其用途
JP2022551662A (ja) Ｂｃｍａを標的とする、ヒトサルの交差反応性を有するヒト化モノクローナル抗体
JP2020527158A (ja) 多重特異性抗体混合物の生成およびその使用方法
JP2022008309A (ja) Ｅｇｆｌ６特異的モノクローナル抗体及びそれらの使用方法
JP2024520577A5 (https=)
CN118290584A (zh) 一种包括nk细胞的药物组合物及其在制备治疗肿瘤药物中的应用
JP2023515821A5 (https=)
CN113980133B (zh) 抗体及其在抗肿瘤中的应用
CN114685675A (zh) 双特异性抗体及其在治疗癌症中的用途
TW202019962A (zh) 標靶CD38及TGF-β的組合療法
CN118047874A (zh) 一种双特异性抗体及其与t细胞在制备治疗肿瘤药物中的应用
JP7162011B2 (ja) 癌糖ペプチドに対するモノクローナルおよびヒト化抗体
CN113956359A (zh) 一种抗体及其在抗肿瘤中的应用
WO2016163433A1 (ja) 抗ｆｇｆｒ２抗体と他剤を含む組成物